Aethlon Medical, Inc. announced on July 15, 2025, that the independent Data Safety Monitoring Board (DSMB) overseeing its Australian oncology clinical trial (AEMD-2022-06) completed its scheduled safety review. The DSMB recommended advancing to the next patient cohort without modification.
The DSMB reviewed data from the initial cohort of three participants, each receiving a single 4-hour Hemopurifier treatment. Based on their evaluation, the board found no safety concerns and confirmed the Hemopurifier's favorable safety and tolerability profile, with no serious adverse events (SAEs) or Dose-Limiting Toxicities (DLTs) reported.
Enrollment for Cohort 2 is now open at the study's three active clinical sites in Australia, where participants will receive two Hemopurifier treatments over a one-week period. This positive recommendation marks a significant step forward in the clinical development program for the Hemopurifier in Oncology.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.